Biguanides Global Market Report 2024

The biguanides market size has grown steadily in recent years. It will grow from $4.79 billion in 2023 to $4.96 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. The growth observed in the historical period can be attributed to several factors, including an increase in demand for oral hypoglycemic drugs, the growth of the geriatric population, rising obesity rates, and heightened awareness about diabetes management.

The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.76 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The anticipated growth in the forecast period is expected to be fueled by factors such as the increasing adoption of combination therapies, advancements in drug delivery technologies, rising investment in research and development, expanding healthcare expenditure, and broadening applications in the treatment of polycystic ovary syndrome. Significant trends projected for this period include a heightened focus on developing extended-release formulations, a growing preference for fixed-dose combination therapies, expanding applications in oncology, and the emergence of novel biguanides with improved efficacy and safety profiles.

The increase in diabetes cases is anticipated to drive the expansion of the biguanides market in the foreseeable future. Diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels due to insufficient insulin production, is on the rise due to various factors such as lifestyle shifts, population aging, genetic factors, improved diagnostic methods, and environmental influences. Biguanides such as metformin help manage diabetes by enhancing insulin sensitivity, reducing liver glucose production, and lowering blood sugar levels in individuals with type 2 diabetes. For example, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals receiving all eight recommended care processes for type 1 and type 2 diabetes increased significantly. Additionally, the percentage of individuals achieving target HbA1c levels reached a record high of 37.9%. Therefore, the increasing prevalence of diabetes is propelling the growth of the biguanides market.

Leading companies in the biguanides market are concentrating on developing advanced solutions such as extended-release formulations to enhance patient compliance, improve therapeutic effectiveness, and minimize side effects. Extended-release biguanides slowly release their active ingredients, ensuring consistent blood levels and better glycemic control for diabetes patients, thereby enhancing treatment adherence. For instance, in August 2023, Dr. Reddy’s Laboratories, an India-based biotechnology company, introduced saxagliptin and metformin hydrochloride extended-release drugs, a generic version of KOMBIGLYZE XR approved by the US Food and Drug Administration (USFDA). This combination medication, consisting of saxagliptin, a DPP-4 inhibitor, and metformin, a biguanide, aims to improve glycemic control in adults with type 2 diabetes mellitus when used in conjunction with diet and exercise. The extended-release formulation enhances patient adherence and efficacy.

In August 2023, Lupin, an India-based biopharmaceutical company, acquired diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed sum. This acquisition enables Lupin to expand its product portfolio and strengthen its position in the anti-diabetes segment, ensuring broader access to medication for patients. Boehringer Ingelheim, a Germany-based biopharmaceutical company, is renowned for its research, development, and production of therapies for both human and veterinary medicine.

Major companies operating in the biguanides market are Cardinal Health Inc., Pfizer Inc., Merck And Co Inc, Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Company Limited, Novo Nordisk A/S, Viatris Inc., Daiichi Sankyo Company Limited, Wanbury Ltd, Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cipla Ltd, Shionogi & Co Ltd, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Apotex Inc, Torrent Pharmaceuticals Limited, Panacea Biotech Ltd., Auro Laboratories Limited.

Asia-Pacific was the largest region in the biguanides market in 2023. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biguanides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Biguanides comprise a class of medications primarily employed in the treatment of type 2 diabetes. They aid in lowering blood sugar levels by reducing the liver's production of sugar and enhancing the body's responsiveness to insulin. Additionally, these medications find utility in treating polycystic ovary syndrome (PCOS) and other metabolic disorders.

The primary types of biguanides include metformin, phenformin, and others. Metformin stands out as a widely utilized biguanide medication for type 2 diabetes management, effectively lowering blood sugar levels. Available in various dosage forms such as tablets and oral solutions, metformin is offered in different formulations including immediate-release and extended-release variants. These medications are distributed through a variety of channels including hospital pharmacies, retail pharmacies, and online platforms.

The biguanides market research report is one of a series of new reports that provides biguanides market statistics, including biguanides industry global market size, regional shares, competitors with a biguanides market share, detailed biguanides market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. This biguanides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.